Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008228 | 0.85 | ALPL (0.43) | ALPLKDM4EALDH1A1HSD17B10NPC1 | |
| SCHEMBL3928928 | 0.83 | ALPL (0.65) | ALPLKDM4EALDH1A1HSD17B10NPC1 | |
| SCHEMBL2171482 | 0.81 | KDM4E (0.59) | ALPLKDM4EALDH1A1HSD17B10NPC1 | |
| SCHEMBL3928703 | 0.76 | ALPL (0.54) | ALPLKDM4EALDH1A1HSD17B10NPC1 | |
| SCHEMBL30290797 | 0.70 | KDM4E (0.51) | ALPLKDM4EALDH1A1HSD17B10NPC1 | |
| SCHEMBL2172075 | 0.70 | KDM4E (0.42) | ALPLKDM4EALDH1A1HSD17B10PGR | |
| SCHEMBL2548371 | 0.70 | ALDH1A1 (0.48) | ALPLKDM4EALDH1A1HSD17B10NPC1 | |
| SCHEMBL2175776 | 0.69 | NPC1 (0.48) | ALPLKDM4EALDH1A1HSD17B10NPC1 | |
| SCHEMBL4149139 | 0.68 | ALPL (0.67) | ALPLKDM4EALDH1A1HSD17B10NPC1 | |
| SCHEMBL3515978 | 0.66 | PDGFRB (0.42) | ALPLKDM4EALDH1A1HSD17B10NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009010824-A1 | DIHYDROCHROMENOPYRAZOLE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS, S.A. (US) | 2009-01-22 | — | — | WO | disclosed |